As of 2026-09-22, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (3,696.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -43586.5%.
The range of the Relative Valuation is (2,390.03) - (4,410.43) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 22.3x | 19.3x |
| Forward P/E multiples | 10.0x - 21.0x | 15.9x |
| Fair Price | (2,390.03) - (4,410.43) | (3,696.36) |
| Upside | -28218.0% - -51987.4% | -43586.5% |
| Date | P/E |